NASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis $2.24 -0.21 (-8.57%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.33 +0.09 (+3.79%) As of 05/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alaunos Therapeutics Stock (NASDAQ:TCRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alaunos Therapeutics alerts:Sign Up Key Stats Today's Range$2.02▼$2.4550-Day Range$1.43▼$4.2252-Week Range$1.31▼$14.20Volume25,824 shsAverage Volume135,362 shsMarket Capitalization$3.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Read More… Alaunos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreTCRT MarketRank™: Alaunos Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Alaunos Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAlaunos Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Alaunos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.11% of the float of Alaunos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlaunos Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alaunos Therapeutics has recently increased by 75.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlaunos Therapeutics does not currently pay a dividend.Dividend GrowthAlaunos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.11% of the float of Alaunos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlaunos Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alaunos Therapeutics has recently increased by 75.43%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.43 News SentimentAlaunos Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alaunos Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for TCRT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.11% of the stock of Alaunos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.72% of the stock of Alaunos Therapeutics is held by institutions.Read more about Alaunos Therapeutics' insider trading history. Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRT Stock News HeadlinesAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 2, 2025 | Crypto 101 Media (Ad)Precigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comSee More Headlines TCRT Stock Analysis - Frequently Asked Questions How have TCRT shares performed this year? Alaunos Therapeutics' stock was trading at $1.90 at the start of the year. Since then, TCRT shares have increased by 17.9% and is now trading at $2.24. View the best growth stocks for 2025 here. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its quarterly earnings data on Tuesday, November, 14th. The company reported ($6.00) EPS for the quarter, missing analysts' consensus estimates of ($4.50) by $1.50. When did Alaunos Therapeutics' stock split? Alaunos Therapeutics's stock reverse split on Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alaunos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings11/14/2023Today5/01/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRT CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,140,000.00 Net MarginsN/A Pretax Margin-196,349.98% Return on Equity-267.77% Return on Assets-209.18% Debt Debt-to-Equity RatioN/A Current Ratio4.30 Quick Ratio4.30 Sales & Book Value Annual Sales$10,000.00 Price / Sales358.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.93 per share Price / Book0.57Miscellaneous Outstanding Shares1,601,000Free Float1,519,000Market Cap$3.59 million OptionableNo Data Beta-0.74 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TCRT) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.